Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Rituximab is a man-made antibody used to treat certain types of cancer. This study will
determine whether rituximab is an effective treatment for adult and pediatric patients with
dermatomyositis or polymyositis.
Study hypotheses: 1) The time to improvement in Group A patients (receiving rituximab first)
will occur significantly earlier than in Group B patients (receiving rituximab later). 2) The
proportion of patients improved at Week 8 of the treatment phase will be significantly
greater in Group A than in Group B.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
Biogen Genentech, Inc. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)